Predicting acute graft versus host disease using blood samples
CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease
Henry Ford Health System · NCT05718791
This study is trying to find specific markers in blood samples that can help predict if patients over 18 will develop severe acute graft versus host disease after receiving a stem cell transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Henry Ford Health System (other) |
| Locations | 1 site (Detroit, Michigan) |
| Trial ID | NCT05718791 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify immunologic signatures that can predict the onset of severe acute graft versus host disease (GVHD) in patients undergoing allogeneic stem cell transplantation. By analyzing blood samples from patients over 18 years old admitted for this procedure, the study seeks to uncover key biomarkers associated with clinical outcomes following different GVHD prophylaxis methods. Understanding these signatures could significantly enhance clinical decision-making and improve patient outcomes in stem cell transplantation.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are being admitted for allogeneic stem cell transplantation for malignant diseases.
Not a fit: Patients who are under 18 years old or not undergoing allogeneic stem cell transplantation for malignant diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better prediction and management of acute GVHD, improving patient outcomes after stem cell transplantation.
How similar studies have performed: While the approach of predicting GVHD using immunologic signatures is being explored, this specific study's methodology may be novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>18 year old admitted for allo SCT PB for malignant disease.
Where this trial is running
Detroit, Michigan
- Henry Ford Health System — Detroit, Michigan, United States (RECRUITING)
Study contacts
- Study coordinator: shatha farhan, MD
- Email: sfarhan1@hfhs.org
- Phone: 3137133910
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: GVHD,Acute